Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.44
At close: Jun 20, 6:56 PM EDT
$1.43
-0.01-0.69%
Pre-Market: Jun 20, 6:56 PM EDT
Comments
Loading...
Gossamer Bio Analyst Ratings and Price Targets | NASDAQ:GOSS | Benzinga
Gossamer Bio Inc has a consensus price target of $7.04 based on the ratings of 14 analysts. The high is $15 issued by Piper Sandler on March 27, 2024. The low is $1.5 issued by Barclays on March 21, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, Wedbush, and Goldman Sachs on May 16, 2025, May 16, 2025, and April 17, 2025, respectively. With an average price target of $6.33 between Goldman Sachs, Wedbush, and Goldman Sachs, there's an implied 342.89% upside for Gossamer Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Wedbush
HC Wainwright & Co.
Oppenheimer
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Gossamer Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | 459.44% | Goldman Sachs | Paul Choi58% | $7 → $8 | Maintains | Buy | Get Alert |
| 05/16/2025 | Buy Now | 179.72% | Wedbush | Laura Chico51% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 04/17/2025 | Buy Now | 389.51% | Goldman Sachs | Paul Choi58% | $8 → $7 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2025 | Buy Now | 179.72% | Wedbush | Laura Chico51% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 01/30/2025 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 179.72% | Wedbush | Laura Chico51% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 06/25/2024 | Buy Now | 529.37% | Oppenheimer | Andreas Argyrides70% | → $9 | Initiates | → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 459.44% | Goldman Sachs | Paul Choi58% | $8 → $8 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $20 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 179.72% | Wedbush | Laura Chico51% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 05/06/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 179.72% | Wedbush | Laura Chico51% | → $4 | Assumes | → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 948.95% | Piper Sandler | Yasmeen Rahimi59% | → $15 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 319.58% | Wedbush | Andreas Argyrides70% | $6 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 459.44% | Goldman Sachs | Paul Choi58% | $9 → $8 | Maintains | Buy | Get Alert |
| 01/08/2024 | Buy Now | 599.3% | HC Wainwright & Co. | Patrick Trucchio49% | $5 → $10 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 319.58% | Wedbush | Andreas Argyrides75% | $6 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 319.58% | Wedbush | Andreas Argyrides70% | $5 → $6 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 249.65% | Wedbush | Andreas Argyrides70% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 249.65% | HC Wainwright & Co. | Patrick Trucchio49% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | 249.65% | Wedbush | Andreas Argyrides70% | $7 → $5 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 249.65% | HC Wainwright & Co. | Patrick Trucchio49% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 389.51% | Wedbush | Andreas Argyrides70% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 05/11/2023 | Buy Now | 249.65% | HC Wainwright & Co. | Patrick Trucchio49% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2023 | Buy Now | 4.9% | Barclays | Carter Gould55% | $2 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 03/07/2023 | Buy Now | 249.65% | Raymond James | Timur Ivannikov37% | → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | — | Guggenheim | Vamil Divan74% | — | Initiates | → Neutral | Get Alert |
| 12/08/2022 | Buy Now | 249.65% | HC Wainwright & Co. | Patrick Trucchio49% | $25 → $5 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 599.3% | Goldman Sachs | Paul Choi58% | $22 → $10 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 459.44% | UBS | Eliana Merle48% | $19 → $8 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | — | JP Morgan | Brian Cheng39% | — | Downgrade | Neutral → Underweight | Get Alert |
| 12/07/2022 | Buy Now | 39.86% | Barclays | Carter Gould55% | $18 → $2 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/07/2022 | Buy Now | 109.79% | SMBC Nikko | David Hoang40% | → $3 | Downgrade | Outperform → Neutral | Get Alert |
| 12/07/2022 | Buy Now | 249.65% | Raymond James | Steven Seedhouse57% | $15 → $5 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 599.3% | SVB Leerink | Joseph Schwartz64% | $15 → $10 | Maintains | Outperform | Get Alert |
| 11/17/2022 | Buy Now | 948.95% | Raymond James | Steven Seedhouse57% | $18 → $15 | Maintains | Outperform | Get Alert |
| 10/20/2022 | Buy Now | 1438.46% | Goldman Sachs | Paul Choi58% | → $22 | Initiates | → Buy | Get Alert |
| 09/21/2022 | Buy Now | 1088.81% | JP Morgan | Brian Cheng39% | → $17 | Initiates | → Neutral | Get Alert |
| 09/19/2022 | Buy Now | 1578.32% | Wedbush | Andreas Argyrides70% | → $24 | Initiates | → Outperform | Get Alert |
| 08/18/2022 | Buy Now | 1158.74% | Barclays | Carter Gould55% | $12 → $18 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 1158.74% | Raymond James | Steven Seedhouse57% | $14 → $18 | Maintains | Outperform | Get Alert |
| 07/14/2022 | Buy Now | 879.02% | Raymond James | Steven Seedhouse57% | $10 → $14 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Gossamer Bio (GOSS) stock?
The latest price target for Gossamer Bio (NASDAQ:GOSS) was reported by Goldman Sachs on May 16, 2025. The analyst firm set a price target for $8.00 expecting GOSS to rise to within 12 months (a possible 459.44% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gossamer Bio (GOSS)?
The latest analyst rating for Gossamer Bio (NASDAQ:GOSS) was provided by Goldman Sachs, and Gossamer Bio maintained their buy rating.
When was the last upgrade for Gossamer Bio (GOSS)?
There is no last upgrade for Gossamer Bio
When was the last downgrade for Gossamer Bio (GOSS)?
The last downgrade for Gossamer Bio Inc happened on March 7, 2023 when Raymond James changed their price target from N/A to $5 for Gossamer Bio Inc.
When is the next analyst rating going to be posted or updated for Gossamer Bio (GOSS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Gossamer Bio (GOSS) correct?
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a maintained with a price target of $7.00 to $8.00. The current price Gossamer Bio (GOSS) is trading at is $1.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
